Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Inventory (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Inventory for 6 consecutive years, with $17.9 million as the latest value for Q3 2018.

  • On a quarterly basis, Inventory rose 17.47% to $17.9 million in Q3 2018 year-over-year; TTM through Sep 2018 was $17.9 million, a 17.47% increase, with the full-year FY2017 number at $16.8 million, up 37.73% from a year prior.
  • Inventory was $17.9 million for Q3 2018 at Theravance Biopharma, roughly flat from $17.9 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $17.9 million in Q3 2018 to a low of $9.4 million in Q1 2016.
  • A 5-year average of $13.4 million and a median of $12.5 million in 2014 define the central range for Inventory.
  • Peak YoY movement for Inventory: decreased 23.76% in 2016, then surged 47.67% in 2018.
  • Theravance Biopharma's Inventory stood at $12.5 million in 2014, then dropped by 20.25% to $10.0 million in 2015, then increased by 22.14% to $12.2 million in 2016, then soared by 37.73% to $16.8 million in 2017, then grew by 6.49% to $17.9 million in 2018.
  • Per Business Quant, the three most recent readings for TBPH's Inventory are $17.9 million (Q3 2018), $17.9 million (Q2 2018), and $17.2 million (Q1 2018).